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N 1979 A MILD FORM of adrenal steroid 21-hydroxylase deficiency (21OHD) called nonclassical steroid 21-hydroxylase deficiency (NC21OHD) was reported (1) . Although a varying clinical severity of congenital adrenal hyperplasia (CAH) had always been observed, this report defined the mild form of 21OHD CAH using specific hormonal and genetic criteria. In 1986 the gene for 21OHD was published (2) , and the molecular genetic mutations specific for the nonclassical form of 21OHD were published (3) (4) (5) . Over the past 20 yr, our team in New York City has followed more than 400 patients, aged 8 months to 69 yr, who presented with NC21OHD. The genotypes for probands and family members of more than 400 affected individuals have been obtained. This is by far the largest group studied with molecular genetic techniques. In this paper, the diagnosis and treatment of NC21OHD will be reviewed, and the high prevalence of this disorder will be discussed. A widely underdiagnosed disorder in children and adults, NC21OHD is a cause of a variety of hyperandrogenic symptoms that are readily treatable in both males and females.
Classical and Nonclassical 21-Hydroxylase Deficiency
CAH refers to a family of inherited disorders in which defects occur in one of five enzymatic steps required to synthesize cortisol from cholesterol in the adrenal gland. Because of the impaired cortisol secretion, ACTH levels rise via a negative feedback system and stimulate adrenal hormone secretion, resulting in hyperplasia of the adrenal cortex. In 21OHD, responsible for 90 -95% of CAH cases, there is an accumulation of the precursors immediately proximal to the 21-hydroxylation step in the pathway of cortisol synthesis, and these precursors are shunted into the androgen pathway ( Fig. 1) .
Three forms of 21OHD CAH can be distinguished by clinical, hormonal, and molecular genetic criteria: the classical salt-wasting, classical simple-virilizing, and nonclassical forms (6) . In the severe classical salt-wasting form, elevated prenatal androgens cause ambiguous genitalia in the affected female fetus, and aldosterone synthesis is impaired. In classical simple-virilizing CAH, aldosterone synthesis is not affected, but affected females present with genital ambiguity. Nonclassical patients secrete aldosterone normally, and NC21OHD-affected females do not have genital ambiguity.
The nonclassical form of 21OHD was discovered during studies of the family members of classically affected patients; some completely asymptomatic family members were discovered to have human lymphocyte antigen (HLA) genetic linkage markers, indicating the presence of mutations at the 21-hydroxylase locus. On hormonal evaluation, diminished 21OH activity was confirmed. All of these individuals later became symptomatic (7) . Subsequently, the molecular genetic basis of NC21OHD was described (5) ( Table 1) .
Clinical Description of NC21OHD
Although NC21OHD females are not born with ambiguous genitalia, a partial deficiency of 21-hydroxylation causes postnatal androgen excess in patients of both sexes, leading to various hyperandrogenic signs that manifest from childhood to adulthood, as summarized in Fig. 2 . All individuals diagnosed with NC21OHD based on molecular genetic testing develop one or more signs of hyperandrogenism over time, including those who were initially asymptomatic (7).
Patients with NC21OHD have extremely variable presentations with one or more hyperandrogenic signs. There have been few large-scale studies of the disorder, partly because it was only recently described but also because there are few clinics with large patient populations, ours in New York City being the largest. The papers published to date that include patients diagnosed by DNA report on small groups of patients (3-5, 8 -13) .
In children, the presenting signs of NC21OHD include premature pubarche (14 -17) , cystic acne ( Fig. 3) (18, 19) , accelerated growth (20) , and advanced bone age (21) (22) (23) (24) . In males and females, premature development of pubic hair may occur as early as 6 months of age (25) . In one study, NC21OHD was found in 30% of children with premature pubarche (14) , whereas a lower prevalence was reported by another group (26) . Of 48 patients with premature pubarche screened in another study, four were found to have NC21OHD (17) . Severe cystic acne refractory to oral antibiotics and retinoic acid has been associated with NC21OHD (27) . Although patients with NC21OHD demonstrate excessive somatic growth and tall stature in early childhood (20) , this growth is arrested because of early epiphyseal fusion, which compromises final height (21, 28, 29) . Thus, patients are tall children but short adults. In our cohort, 31 of 45 (69%) children with a genetic and hormonal diagnosis of NC21OHD and bone age recorded at or before age 12 had a bone age advancement of 2 yr or more. Treatment for this problem with human GH and LHRH analog has recently been reported by Lin-Su et al. (56) . In this report, the children with NC21OHD treated for advanced bone age with human GH and LHRH analog achieved their target height when treatment began before the bone age was 12 yr.
Little has been published about males with NC21OHD. Typically, males with NC21OHD do not suffer from impaired gonadal function and tend to have normal sperm counts (23, 30) . However, manifestations of adrenal androgen excess may include short stature or oligospermia and diminished fertility (23, 31, 32) . Importantly, reversal of infertility and oligospermia upon treatment with glucocorticoids has been observed (23, (33) (34) (35) .
Women with NC21OHD can suffer from gonadal dysfunction and menstrual disorders including amenorrhea, anovulation, oligomenorrhea (7, 25, 36) , and infertility (10, 37) . Previous studies suggest that these irregularities may be due to the conversion of excess adrenal androgens to estrogens, which then disrupt gonadotropin secretion (38, 39) . In one multicenter study by Speiser et al. (40) , 26 women carrying one severe and one mild CYP21A2 mutation were said to be infertile. However, some of the women did not attempt to conceive and some may have conceived after treatment. In a recent study of 18 Croatian patients (10 males, eight females) with NC21OHD, all four women of reproductive age were fertile and all had conceived before treatment (41) . Molecular genetic analysis of these women did not show correlation of fertility with genotype, although 50% were homozygous for the mild exon 7 mutation. Another study by Rumsby et al. (10) found that of six genetically characterized NC21OHD women, two had primary infertility, and four eventually succeeded in giving birth after experiences of miscarriage and other complications. In this small sample of six women, individuals with the exon 7 mutation in conjunction with a severe mutation presented with oligomenorrhea, whereas those homozygous for the exon 7 mutation had regular cycles and one was fertile. Thus, data from studies of small groups of patients with NC21OHD have been variable. Some women with NC21OHD present with polycystic ovary syndrome (PCOS) (43) (44) (45) . In these cases, adrenal sex steroid excess disrupts the cyclicity of gonadotropin release or directly affects the ovary, leading to the formation of ovarian cysts. These cysts may then autonomously produce androgens to compromise fertility. A 2003 consensus statement defined the diagnostic criteria of PCOS as the presence of two of the following three findings: 1) polycystic ovaries by sonography, 2) clinical or biochemical evidence of androgen excess, and 3) chronic menstrual abnormalities or anovulation, in addition to exclusion of other known disorders (46). NC21OHD also presents with hyperandrogenemia and anovulation, and thus should be ruled out in patients with PCOS. The frequency of NC21OHD in PCOS has not been determined in a large series. A study by Stikkelbroeck et al. (47) of 13 patients with CAH found that polycystic ovaries were no more frequent in female CAH patients than the general population; however, all patients had been treated since the diagnosis of CAH was made (11 of 13 had DNA confirmation of the diagnosis). The treatment may have resulted in a reversal of signs of PCOS. On the other hand, several studies have shown that CAH patients may exhibit ovarian adrenal rest tumors (48, 49) which, on ultra- sound, may be difficult to differentiate from cystic ovarian tissue (50) . A recent report from Montréal, Canada, by Dr. Geoffrey Hendy indicated that 10% of PCOS patients were proven to have NC21OHD (Hendy, G., personal communication). It has been recognized that infertility of undetermined cause in women may be reversed with glucocorticoid therapy. In one report, five females with irregular menses and high 17-keto(oxo)steroids resumed regular menses and demonstrated adequate suppression of 17-ketosteroids and pregnanetriol within 2 months of beginning glucocorticoid therapy (51) . This suggests the presence of an adrenal 21-hydroxylating defect, although no molecular genetic diagnosis was carried out (51) . In another report of 18 infertile women with acne and/or facial hirsutism and hormonal criteria consistent with 21OHD (without molecular genetic confirmation of the disease), seven conceived shortly after initiating prednisone treatment alone; an additional four women conceived within 2 months of the addition of clomiphene to the therapeutic regimen (52) . Hormonal profiles after initiation of therapy were not reported in this study.
Females with NC21OHD may present with hirsutism. In one study of 20 females with NC21OHD, 39% had isolated hirsutism (53) . These studies did not include genetic analysis because they were published before the technique was available for diagnosis. Additionally, male-pattern baldness, classified by Ludwig scores (54), can be the sole presenting symptom of NC21OHD (Fig. 4) .
In our large cohort of patients with NC21OHD, there were 28 women with the diagnosis of NC21OHD confirmed by genetic and hormonal analysis whose hirsutism was evaluated by Ferriman-Gallwey scores (55) . Of the 28 NC21OHD women, 20 (71%) had scores above 8, and 15 (54%) had scores above 15. Ferriman-Gallwey scores of 8 or higher indicated significant hirsutism.
Hormonal Features
The most definitive hormonal diagnostic test for 21OHD is an ACTH (Cortrosyn 0.25 mg) stimulation test, which measures the serum concentrations of 17-hydroxyprogesterone (17-OHP) at 0 and 60 min after ACTH administration. Test values may be plotted in a nomogram (Fig. 5) , which reflects the different degrees of hormonal compromise in patients with classical and nonclassical 21OHD, and heterozygous carriers of a CYP21A2 mutation (57) . As indicated by the nomogram, patients with NC21OHD typically aggregate midway down the regression line with 60-min stimulated 17-OHP values between 1,000 and 10,000 ng/dl.
In rare instances, nonclassical patients have had hormonal measurements in the neonatal period and early infancy (Table 2). Although we have very few hormone analyses in the neonate, it appears that hormone values are variable. In the two infants without prenatal treatment we observed, 17-OHP is elevated in both the male and female, whereas testosterone and ⌬ 4 -androstenedione were elevated only in the female. However, additional studies are required. In the fetus treated until term, the values were low, although the newborn had not shown signs of adrenal insufficiency.
Psychobiology of NC21OHD
NC21OHD appears to affect selected psychological domains, presumably through the effects of elevated androgen levels in the brain and/or by way of psychological reactions to clinical androgen-dependent symptoms. In a recent study, Meyer-Bahlburg et al. (58) showed slightly but significantly increased masculinization/defeminization on several measures of gender-related behavior in NC21OHD women when compared with normal control women, although markedly less so than in women with classical CAH. Similarly, a recent abstract from the same study indicated that the NC21OHD women had significantly increased bisexual or homosexual orientation (59) . However, the sexual functioning of N21OHD women did not differ from that of normal control women, unlike women with classical CAH who as a group showed impaired sexual functioning (60) . Retrospective clinical-qualitative interviews with these women revealed a history of discomfort and social stress related to their pretreat- 
Molecular Genetics
Hormonally and clinically defined nonclassical and classical forms of CAH are associated with distinct genotypes (Table 1) . These genotypes are characterized by varying levels of enzyme activity, as defined by in vitro expression studies (61) (62) (63) .
The gene encoding 21-hydroxylase is a microsomal cytochrome P450 termed CYP21A2 (64) (Fig. 6 ) (previously P450c21) mapped to the short arm of chromosome 6 within the HLA complex (65) .
Understanding of the CYP21A2 gene has been advanced, including its characterization in terms of location, duplication in tandem with the fourth component (C4) isotypes, structure, and the sequencing of the gene and its pseudogene and their arrangement on the chromosome (66 -70) . The CYP21A2 gene and its homolog, the pseudogene CYP21A1P, alternate with two genes called C4B and C4A (70, 71) that encode the two isoforms of C4 of serum complement (Fig. 6 ) (72).
The CYP21A2 and CYP21A1P genes, which each contain 10 exons, share 98% sequence homology in exons and approximately 96% sequence homology in introns (Fig. 7) . In a large percentage of the patients with NC21OHD, the exon 7 (V281L) mutation has been associated with a duplication of the pseudogene and the C4B gene (73, 74) . This is especially common in patients with the HLA haplotype B14DR1.
The deletional mutations of the 21OHD genes and characterized specific point mutations of the CYP21A2 gene have been reported (75) . The most common mutations appear to be the result of one of two types of meiotic recombination between CYP21A2 and CYP21A1P: 1) misalignment and unequal crossing over, resulting in large-scale DNA deletions, and 2) apparent gene conversion events that result in the transfer of smaller-scale deleterious mutations present in the CYP21A1P pseudogene to the CYP21A2 gene. To date, approximately 103 mutations in the CYP21A2 gene have been reported (75) (see Table 1 for the most common mutations).
The genotype for the classical form of 21OHD is predicted to be a severe mutation on both alleles at the 21-hydroxylase locus, with markedly reduced enzymatic activity generally associated with salt wasting. The point mutation A (or C) to G near the end of intron 2, which is the single most frequent mutation in classical 21OHD, causes premature splicing of the intron and a shift in the translational reading frame (63, 76) . Most patients who are homozygous for this mutation have low or absent serum aldosterone levels and the severe salt-wasting form of the disorder (77, 78) . One mutation in exon 4 (I172N), specifically associated with simple-virilizing 21OHD (79), has been shown by in vitro expression studies to result in 1% of normal enzyme activity (79) . Adrenal production of aldosterone is normally in the range of 1:100 to 1:1000 that of cortisol. The very low residual activity of the I172N mutation apparently is still able to allow aldosterone synthesis and thus prevent significant salt wasting in most cases of the simple-virilizing form of 21OHD.
In contrast to the classical form, patients with NC21OHD are predicted to have mild mutations on both alleles or one severe and one mild mutation of CYP21A2 (compound heterozygote). Missense mutations in exon 7 (V281L) and exon 1 (P30L), which are predominantly associated with nonclassical disease, reduce enzymatic activity in cultured cells to 20 -50% of normal (80) . Nonclassical patients have normal aldosterone secretion and therefore do not experience salt wasting. A recent report found that missense mutations in exon 8 (R339H) and exon 10 (P453S) are associated with the nonclassical phenotype as well (84) (Table 1).
21OHD Genotype-Phenotype Correlations
In 98% of 21OHD patients, genotype corresponds with hormonal phenotype; however, rare cases of nonconcordance have important implications in prenatal diagnosis of 21OHD and genetic counseling (78) . In our large cohort of 
Frequency of NC21OHD
Through studies of kindreds including a proband with classical or NC21OHD (82) and molecular screening of the 21-hydroxylase alleles of the heterogeneous population of New York City (83), the frequency of NC21OHD has been estimated to be 1:100, making it the most common of all autosomal recessive diseases, even more common than sickle cell anemia, Tay-Sachs, cystic fibrosis, and phenylketonuria (a disease for which newborn screening is mandated in every state in the United States) (Fig. 8) . Screening for classical CAH is conducted in 48 states in the United States. The nonclassical form of CAH is not detected by hormonal screening. This would require DNA screening, which is not yet available.
Because the gene for this disorder is autosomal, it occurs equally in men and women. It appears that males are significantly underdiagnosed. Of our 440 nonclassical patients, 344 are females and only 96 are males (unpublished data), indicating that males are infrequently diagnosed.
A higher frequency of NC21OHD was reported in certain ethnic groups (82) . The results of this study were supported by a subsequent study of a random population of 100 people (83) , which confirmed the highest ethnic-specific frequency to occur in the Ashkenazi Jews at 1:27 (82) . Interestingly, whereas the prevalence of NC21OHD in Ashkenazi Jews is high, there is no increased prevalence of the severe classical form of 21OHD in this population (82) . Other ethnic groups with high disease frequency included Hispanics (1:40), Slavs (1:50), and Italo-Americans (1:300) ( Table 3 ) (82) (83) (84) (85) (86) . These data were based on small groups that have recently been studied in larger groups (Wilson, R., S. Nimkarn, M. Dumic, J. Obeid, M. Azar, H. Najmabadi, F. Saffari, M. New, unpublished data).
The disparity in frequency of NC21OHD reported by different authors may be attributed to differences in ethnicity of study populations (6) . In a study of 317 probands with NC21OHD, the most common genotype found was exon 7/ exon 7 (V281L), which occurs most frequently in the Ashkenazi Jews. Table 4 presents data gathered from probands in common ethnic groups and their respective genotype frequencies (unpublished data).
Dr. Robert Wilson (Mount Sinai School of Medicine, New York, NY) has analyzed the molecular genotypes of more than 1300 patients with classical and NC21OHD over the past 10 yr and has identified more than 10 new mutations in the CYP21A2 gene in exons 5, 6, 8, 9, and 10. The mutations are in exon 1 (H62L), exon 2 (R91X), exon 5 (H203Y), exon 8 (R316L, R341P, Q351K, and H365Y), and exon 10 (R426H; L442-1 nt; L433P; A457-1 nt; and a 9-bp deletion eliminating codons G424, A425, and R426) (unpublished data). In patients who demonstrate hormonal abnormalities indicating NC21OHD but whose genotype reveals only heterozygosity, we sequence the CYP21A2 gene to establish a second mu- Dex, Prenatal dexamethasone treatment; Amnio, amniocentesis; CVS, chorionic villus sampling. 
Prenatal Diagnosis and Treatment of NC21OHD
We have made the prenatal diagnosis of NC21OHD in both males and females (Tables 5 and 6 ). The diagnosis was made by molecular genetic techniques, except for one female patient in which the diagnosis was made by HLA genotyping, as the patient was born in 1991 before routine molecular genetic testing was available. The genetic diagnosis was made on cells from amniocentesis and tissue from chorionic villus sampling (Fig. 9) . In the newborn females, the genitalia were normal female whether or not dexamethasone treatment was administered to the mother according to the algorithm in Fig. 10 . The treatment with dexamethasone was administered to the mother from the fourth to 10th week of gestation until term to four female fetuses. The male fetuses were partially treated from the first to 18th week of gestation. One male fetus was treated until term (Table 6 ) because the karyotype was initially reported erroneously as 46,XX and the genitalia on sonography showed a large phallic structure. The exon 7, 1, and 10 mutations have been associated with the nonclassical phenotype. The genotypes of the patients included an exon 7 (V281L) mutation in all female fetuses and in nine of the 10 male fetuses. The remaining male fetus had an exon 1 mutation. Two male fetuses were homozygous for the exon 7 mutation, whereas five female fetuses were ho- mozygous for the exon 7 mutation. No fetuses carried the exon 10 mutation. The diagnosis was confirmed postnatally by hormonal tests.
Treatment and Reversal of Signs Response to therapy of hyperandrogenic signs
The preliminary results in 20 females (91) suggest that screening would be beneficial and cost-effective in infertility and dermatology clinics. Irregular menstruation and acne are reversed within 3 months of treatment with dexamethasone (0.25 mg at the hour of sleep each day) (Fig. 11) , whereas hirsutism may be reversed within 30 months (91) . More studies on the response of NC21OHD to treatment must be performed. Correlation of genotype with remission and/or recrudescence of signs in response to treatment also warrants further investigation.
Treatment of short stature in children with NC21OHD
Children with NC21OHD do not achieve a final height that is owed them by their parents because they frequently suffer an advanced bone age and arrest their growth early. Some are very short (24, 28) . However, there is now treatment with human GH and/or LHRH analog to increase the final height so that children will achieve the target height predicted from the heights of the parents (56) .
Importance of Heightened Awareness of NC21OHD
Signs of hyperandrogenemia are of great concern to the American population, as evidenced by the expenditures on acne, hirsutism, frontal balding, and infertility. Table 7 indicates the money spent annually on current treatments for various signs of hyperandrogenemia. NC21OHD could be more effectively and economically treated with lowcost glucocorticoid treatment. Recently, infertility has been treated by assisted reproductive techniques including in vitro fertilization and intracytoplasmic sperm injection. Generally, one cycle of in vitro fertilization costs $30,000 and patients often undergo more than one cycle, with the second cycle followed by intracytoplasmic sperm injection at $2,500 per injection. In properly diagnosed nonclassical patients, fertility could be restored through inexpensive oral treatment with glucocorticoids, rather than difficult and expensive interventions. NC21OHD should be suspected and diagnosed in patients with hyperandrogenism, especially patients in ethnic groups at high risk for NC21OHD.
Although hyperandrogenic signs in NC21OHD are not fatal, they do cause anguish in many patients: severe acne in adolescents is often disabling, causing young patients to withdraw from social function. Loss of scalp hair in females and males is embarrassing, requiring treatment with 5␣-reductase inhibitors and other hair-restoring treatments. Hirsutism, requiring shaving in women, is unacceptable to women who then undergo new treatments such as laser and depilatory treatment at great expense. Preliminary studies of the reversal of hyperandrogenic signs in patients with NC21OHD indicate that it took about 3 months of treatment to reverse acne and infertility (91) . The treatment required for this reversal is generally 0.25 mg dexamethasone at the hour of sleep. The cost for a dexamethasone tablet is $0.50, and the 3-month treatment cost is estimated to be $45. Clearly, proper diagnosis and treatment of NC21OHD is cost-effective.
In summary, NC21OHD is a widely underdiagnosed disease causing a variety of hyperandrogenic symptoms, which are easily treated with glucocorticoid therapy. The availability of DNA analysis may encourage populations at risk for NC21OHD to obtain diagnosis and treatment. In ethnic groups such as Ashkenazi Jews, in whom the disease has a high prev- alence, the diagnosis of NC21OHD should be considered. Genotyping is currently available and facilitates the diagnosis of NC21OHD. Because this disease is frequent and treatment is easy and cost-effective, it behooves clinicians to suspect the diagnosis in patients with hyperandrogenic symptoms.
